The publicly listed in vitro diagnostic group is restructuring its capital with the arrival of IK Partners and a pool of investors, alongside Nextstage, which is reinvesting. Eurobio Scientific is a major player in the field of in vitro diagnostics. It is involved in the research and commercialization of diagnostic tests in the areas of transplantation, immunology, infectious diseases, and offers reagents dedicated to research laboratories, including those for pharmaceutical and biotechnology companies. The Group employs approximately 320 people, operates four production units, and has several subsidiaries across Europe. In 2023, it generated €27.3 million in EBITDA for €130 million in revenue. Eurobio Scientific’s shares are listed on Euronext Growth Paris.

Eurobio Scientific and EB Development announced the success of their public takeover bid initiated by the latter, based on the results published on December 18 by the French Financial Markets Authority (AMF) following the reopening period of the offer. As a result, EB Development, acting in concert with NextStage AM, IK Partners, and a consortium of investors represented by Jérôme de Castries, now holds 89% of the capital and voting rights of Eurobio Scientific.

LL Berg (Olivier Abergel, Julien Carrascosa, Léonie Bontoux, and Clément Boissy) acted on behalf of this consortium of new investors represented by Jérôme de Castries.